MEP6708A - Derivati n/tiayol/2/yl/benyamida - Google Patents

Derivati n/tiayol/2/yl/benyamida

Info

Publication number
MEP6708A
MEP6708A MEP-67/08A MEP6708A MEP6708A ME P6708 A MEP6708 A ME P6708A ME P6708 A MEP6708 A ME P6708A ME P6708 A MEP6708 A ME P6708A
Authority
ME
Montenegro
Prior art keywords
thiazol
benzamide derivatives
agonists
receptor
implicated
Prior art date
Application number
MEP-67/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Anette Graven Sams
Mogens Larsen
Gitte Mikkelsen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MEP6708A publication Critical patent/MEP6708A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MEP-67/08A 2003-10-27 2004-10-25 Derivati n/tiayol/2/yl/benyamida MEP6708A (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301579 2003-10-27
DKPA200400229 2004-02-13
PCT/DK2004/000733 WO2005039572A1 (en) 2003-10-27 2004-10-25 N-thiazol-2-yl-benzamide derivatives

Publications (1)

Publication Number Publication Date
MEP6708A true MEP6708A (xx) 2010-02-10

Family

ID=34524309

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-67/08A MEP6708A (xx) 2003-10-27 2004-10-25 Derivati n/tiayol/2/yl/benyamida

Country Status (28)

Country Link
US (2) US20060154974A1 (pl)
EP (2) EP1803455A1 (pl)
JP (1) JP2007509083A (pl)
KR (1) KR20060093726A (pl)
AR (1) AR047621A1 (pl)
AT (1) ATE354365T1 (pl)
AU (1) AU2004283019A1 (pl)
BR (1) BRPI0415661A (pl)
CA (1) CA2542816A1 (pl)
CO (1) CO5690582A2 (pl)
CY (1) CY1106526T1 (pl)
DE (1) DE602004004925T2 (pl)
DK (1) DK1682129T3 (pl)
EA (2) EA010790B1 (pl)
ES (1) ES2279414T3 (pl)
HR (1) HRP20070194T3 (pl)
IL (1) IL175189A0 (pl)
IS (1) IS8364A (pl)
ME (1) MEP6708A (pl)
MX (1) MXPA06004436A (pl)
NO (1) NO20062417L (pl)
PL (1) PL1682129T3 (pl)
PT (1) PT1682129E (pl)
RS (1) RS20060289A (pl)
SG (1) SG147472A1 (pl)
SI (1) SI1682129T1 (pl)
TW (1) TW200524887A (pl)
WO (1) WO2005039572A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060106040A1 (en) 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
TW200524887A (en) * 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
US7910613B2 (en) 2004-09-22 2011-03-22 H. Lundbeck A/S 2-acylaminothiazole derivatives
TW200720264A (en) * 2005-04-25 2007-06-01 Lundbeck & Co As H Pro-drugs of n-thiazol-2-yl-benzamide derivatives
US7674912B2 (en) 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
US20100280023A1 (en) * 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
CA2617817C (en) * 2005-08-02 2014-05-27 Kyowa Kirin Co., Ltd. Thiazole derivatives for treating or preventing sleep disorders
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
RU2483722C1 (ru) * 2012-05-22 2013-06-10 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Аминотиазольные производные усниновой кислоты как новые противотуберкулезные агенты
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
WO2015092420A1 (en) 2013-12-20 2015-06-25 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
ES2578363B1 (es) * 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE855120C (de) * 1950-10-08 1953-01-05 Schering Ag Verfahren zur Herstellung von Aminosalicylsaeureamiden
JP2903339B2 (ja) * 1990-10-12 1999-06-07 大日精化工業株式会社 電子写真感光体
US6121301A (en) * 1996-10-24 2000-09-19 Zeria Pharmaceutical Co., Ltd. Substituted benzoylaminothiazole derivatives and drugs containing the same
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
MXPA03006510A (es) * 2001-01-26 2003-10-15 Shionogi & Co Compuestos halogenados que muestran agonismo del receptor de trombopoyetina.
US7429593B2 (en) * 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US6624163B2 (en) * 2001-11-29 2003-09-23 Hoffman-La Roche Inc. Benzothiazole derivatives
US6713499B2 (en) * 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
TW200524887A (en) * 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
JP4638355B2 (ja) * 2003-12-26 2011-02-23 協和発酵キリン株式会社 チアゾール誘導体
US7674912B2 (en) * 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives

Also Published As

Publication number Publication date
EA200600860A1 (ru) 2006-08-25
KR20060093726A (ko) 2006-08-25
NO20062417L (no) 2006-05-26
US20090247593A1 (en) 2009-10-01
CA2542816A1 (en) 2005-05-06
CO5690582A2 (es) 2006-10-31
IS8364A (is) 2006-03-20
US20060154974A1 (en) 2006-07-13
HRP20070194T3 (hr) 2007-06-30
AU2004283019A1 (en) 2005-05-06
BRPI0415661A (pt) 2006-12-19
ATE354365T1 (de) 2007-03-15
SG147472A1 (en) 2008-11-28
DK1682129T3 (da) 2007-06-11
EP1682129B1 (en) 2007-02-21
RS20060289A (sr) 2008-06-05
EP1682129A1 (en) 2006-07-26
TW200524887A (en) 2005-08-01
CY1106526T1 (el) 2012-01-25
JP2007509083A (ja) 2007-04-12
WO2005039572A1 (en) 2005-05-06
SI1682129T1 (sl) 2007-06-30
PT1682129E (pt) 2007-04-30
EP1803455A1 (en) 2007-07-04
EA200801734A1 (ru) 2008-12-30
DE602004004925D1 (de) 2007-04-05
IL175189A0 (en) 2006-09-05
ES2279414T3 (es) 2007-08-16
EA010790B1 (ru) 2008-10-30
MXPA06004436A (es) 2006-06-20
AR047621A1 (es) 2006-02-01
PL1682129T3 (pl) 2007-07-31
DE602004004925T2 (de) 2007-10-31

Similar Documents

Publication Publication Date Title
SG147472A1 (en) N-thiazol-2-yl-benzamide derivatives
NO20062950L (no) 5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet
TW200503710A (en) Novel compounds
NO20054404L (no) 5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon
MXPA05008524A (es) Pirazoles y metodos de elaboracion y uso de los mismos.
MY135841A (en) Novel benzodioxoles
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
GB0325956D0 (en) Novel compounds
NZ544591A (en) Pyrrolodihydroisoquinolines as PDE10 inhibitors
EA200500017A1 (ru) Новые соединения
MXPA04004370A (es) Derivados policiclicos de guanina inhibidores de fosfodiesterasa v.
MXPA05010652A (es) Pirazoles sustituidos.
ATE512957T1 (de) Hemmer der akt aktivität
TW200503713A (en) Novel compounds
MXPA05010630A (es) Compuestos de benzopirano utiles para tratar estados inflamatorios.
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
MXPA05011962A (es) Oxiarenos substituidos.
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
MXPA04006266A (es) Pirimidotriazinas como inhibidores de fosfatasa.
MY128241A (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
NO20072060L (no) 2-acylaminotiazolderivater
TW200621752A (en) Pyrimidinylpyrazoles and methods of making and using the same
DE50201565D1 (de) 2-thio-subsituierte imidazolderivative und ihre verwendung in der pharmazie